GSK. GSK shall work exclusively with CureVac on the Development, Manufacture and Commercialization of mRNA-Based vaccine and mRNA-Based antibody products targeting the SARS-CoV-2 Pathogen, and GSK shall not, and shall procure that its Affiliates and Sublicensees holding rights to the CureVac Technology in the Field and in the Territory will not, develop, manufacture or commercialize, solely or with a Third Party, any mRNA-Based vaccine or mRNA-Based antibodies targeting the SARS-CoV-2 Pathogen other than a COVID Product Developed and/or Commercialized under this Agreement. This Section 2.3.1 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party's Affiliates) that becomes an Affiliate of GSK solely as a result of a Change of Control in GSK, provided that such activities are performed without using the mRNA technology described in the Know-How, or within the scope of the specification of the Patents Rights, Controlled by GSK (excluding, for clarity any CureVac Know-How or CureVac Patent Rights). Notwithstanding the foregoing, GSK shall be permitted to perform Development and Manufacturing activities with respect to any mRNA-Based vaccine or mRNA-Based antibodies targeting the SARS-CoV-2 Pathogen, using the SARS-CoV-2 spike protein as an Antigen, up to (and including) [*****], provided that GSK shall not be permitted to Commercialize any mRNA-Based vaccine or mRNA-Based antibodies targeting the SARS-CoV-2 Pathogen, or to grant any Third Party a license to Commercialize any mRNA- Based vaccine targeting the SARS-CoV-2 Pathogen.
GSK. (NO. 1) SCOTTISH LIMITED PARTNERSHIP, a private fund limited partnership registered in Scotland with registration number SL035527 and whose principal place of business is at 00 Xxxxxxx Xxxx, Xxxxxxxx Xxxxxx, Xxxxxxxxx, XX0 0XX (“SLP1”);
GSK. GSK shall keep, and require its Affiliates and Sublicensees to keep, complete, true and accurate books of accounts and records for the purpose of determining the amounts payable to XenoPort pursuant to this Agreement. Such books and records shall be kept for at least [… * …] following the end of the calendar quarter to which they pertain and shall be open for inspection and audit by XenoPort during such [… * …] period on the terms of this Section 7.4(a). Upon not less than [… * …] prior written notice, GSK shall permit an independent, certified public accountant selected by XenoPort and reasonably acceptable to GSK, which acceptance will not be unreasonably withheld or delayed (for the purposes of this Section 7.4(a), the “Auditor”), to audit or inspect those books or records of GSK that relate to Net Sales and Payment Reports, and/or Joint P&L (including the components thereof) for the sole purpose of verifying the: * CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
GSK. GSK shall work exclusively with CureVac on the Development, Manufacture and Commercialization of Products targeting a Collaboration Pathogen, and GSK shall not, and shall procure that its Affiliates and Sublicensees holding rights to the CureVac Technology in the Field and in the Territory will not, develop, manufacture or commercialize, solely or with a Third Party, any prophylactic and/or therapeutic mRNA-Based vaccine or mRNA-Based antibody targeting a Collaboration Pathogen other than a Product Developed and/or Commercialized under this Agreement. This Section 2.3.1 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party’s Affiliates) that becomes an Affiliate of GSK solely as a result of a Change of Control in GSK, provided that such activities are performed without using the mRNA technology described in the Know-How, or within the scope of the specification of the Patents Rights, Controlled by GSK (excluding, for clarity any CureVac Know-How or CureVac Patent Rights). Notwithstanding the foregoing, GSK shall be permitted to continue development activities targeting the same Collaboration Pathogen immediately prior to the Effective Date, and which accordingly fall within the scope of the exclusivity commitment set out in this Section 2.3.1, for up to [*****] from the Effective Date, whilst GSK carries out an orderly wind-down of those activities.
GSK. Boostrix- Highlights of prescribing information. Information leaflet Boostrix vaccine. Available at: xxxxx://xxx.xxxxxxxxx.xxx/pharma/content/dam/GlaxoSmithKline/US/en/Prescri- bing_Information/Boostrix/pdf/BOOSTRIX.PDF. Accessed May 19, 2020.
GSK. GSK warrants and represents to Unigene that, as of the Amendment Effective Date:
GSK. Santarus acknowledges that GSK is self-insured. GSK shall maintain self-insurance at levels at least consistent with the levels of insurance described for sub-distributors in this Section 9.5.2 during the Term and for a period of [***] thereafter. GSK shall ensure that its sub-distributors maintain CGL insurance, including broad form contractual liability, and product liability coverages, in an amount of at least [***] Dollars ($[***]) and in an amount of at least [***] Dollars ($[***]) for bodily injury and property damage during the Term and thereafter for a period of [***]. GSK shall give Santarus at least [***] days prior written notice of any cancellation or termination of such insurance. The minimum level of insurance set forth herein will not be construed to create a limit on GSK’s or its sub-distributors’ liability with respect to its indemnification obligations hereunder. GSK shall give Santarus at least [***] days notice of any cancellation or termination of such insurance. GSK will furnish to Santarus a certificate of insurance evidencing such coverage (or evidence reasonably acceptable to Santarus of GSK’s level of self-insurance) as of the Effective Date and upon reasonable request by Santarus at any time thereafter.
GSK. GSK warrants and represents to Unigene that:
GSK. GSK hereby:
GSK. For the attention of: Company Secretary of GSK The registered office from time to time of GSK xxxxxxx.xxx@xxx.xxx With a copy (not constituting notice) to: Xxxxxx Xxxxxxx Xxxxxxxxx and May, One Bunhill Row, London EC1Y 8YY xxxxxx.xxxxxxx@xxxxxxxxxxxxxxx.xxx Pfizer For the attention of: Xxxxxx X. Xxxxxxxx The registered office from time to time of Pfizer With a copy (not constituting notice) to: Xxxxx X. Xxxxx Xxxxxxxx, Xxxxxx, Xxxxx & Xxxx, 00 Xxxx 00xx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000 XXXxxxx@xxxx.xxx SLP1 For the attention of: Company Secretary of GSK The registered office from time to time of GSK xxxxxxx.xxx@xxx.xxx With a copy (not constituting notice) to: Xxxxxx Xxxxxxx Xxxxxxxxx and May, One Bunhill Row, London EC1Y 8YY xxxxxx.xxxxxxx@xxxxxxxxxxxxxxx.xxx SLP2 For the attention of: Company Secretary of GSK The registered office from time to time of GSK xxxxxxx.xxx@xxx.xxx With a copy (not constituting notice) to: Xxxxxx Xxxxxxx Xxxxxxxxx and May, One Bunhill Row, London EC1Y 8YY xxxxxx.xxxxxxx@xxxxxxxxxxxxxxx.xxx SLP3 For the attention of: Company Secretary of GSK The registered office from time to time of GSK xxxxxxx.xxx@xxx.xxx With a copy (not constituting notice) to: Xxxxxx Xxxxxxx Xxxxxxxxx and May, One Bunhill Row, London EC1Y 8YY xxxxxx.xxxxxxx@xxxxxxxxxxxxxxx.xxx GSK Bank Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB xxxxxxx.xxxxxxx@xxxx.xxx With a copy (not constituting notice) to: Equity Syndicate Desk; Xxxxx Xxxxxxx Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB Pfizer Bank For the attention of: Head of Equity Capital Markets Xxxxxx Xxxxxxx & Co. International plc, 00 Xxxxx Xxxxxx, Xxxxxx Xxxxx, Xxxxxx, X00 0XX xxxxxx@xxxxxxxxxxxxx.xxx provided that a Party may change its notice details on giving notice to the other Parties of the change in accordance with this clause 8.2.
